BOK-MCL1 transmembrane interactions: a challenging target for cancer therapy

Mónica Sancho; Mar Orzáez

doi:10.1080/23723556.2020.1859918

BOK-MCL1 transmembrane interactions: a challenging target for cancer therapy

Mol Cell Oncol. 2021 Jan 11;8(1):1859918. doi: 10.1080/23723556.2020.1859918.

Authors

Mónica Sancho¹, Mar Orzáez¹

Affiliation

¹ Laboratorio de Péptidos y Proteínas, Centro de Investigación Príncipe Felipe, Valencia, Spain.

Abstract

Myeloid cell leukemia 1 (MCL1) gene amplification occurs in a wide range of human cancers and protein overexpression associates with malignant cell growth and evasion of apoptosis. We recently reported that disrupting the interaction between the transmembrane domains of MCL1 and BCL-2 related ovarian killer (BOK) induces cell death, thereby suggesting a new target site for anti-tumorigenic strategies.

Keywords: Apoptosis; BCL-2; BOK; MCL1; transmembrane domain.

Grants and funding

This work was supported by the Spanish Ministry of Economy and Competitiveness [Grant SAF2017-84689-R]; Generalitat Valenciana [Grant PROMETEO/2019/065].